Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma
Author:
Affiliation:
1. Department of Surgery & Cancer, Imperial College London, London, UK
Funder
not
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1828348
Reference104 articles.
1. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
2. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
3. Genomic Classification of Cutaneous Melanoma
4. BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
5. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study;Cells;2024-02-20
2. Introduction to Cancer Genetics and Its Symbiotic Relationship;Synbiotics for the Management of Cancer;2023
3. Cyclin-dependent kinases as potential targets for colorectal cancer: past, present and future;Future Medicinal Chemistry;2022-07
4. Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase 4/6 degradation and inhibits melanoma proliferation;Journal of Biological Chemistry;2022-06
5. Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer;Frontiers in Pharmacology;2022-05-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3